WILLIAM PEACOCK to Atrial Fibrillation
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Atrial Fibrillation.
Connection Strength
1.045
-
Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. Am J Cardiol. 2017 Mar 01; 119(5):753-759.
Score: 0.293
-
CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. Ann Emerg Med. 2017 May; 69(5):541-550.e1.
Score: 0.293
-
Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation. Vasc Health Risk Manag. 2009; 5:783-91.
Score: 0.178
-
The role of atrial fibrillation in the short-term outcomes of patients with acute heart failure. Clin Res Cardiol. 2019 Jun; 108(6):622-633.
Score: 0.084
-
Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. Curr Med Res Opin. 2016 07; 32(7):1277-9.
Score: 0.070
-
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. Crit Pathw Cardiol. 2013 Sep; 12(3):107-15.
Score: 0.058
-
Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail. 2013 Jun; 1(3):192-9.
Score: 0.057
-
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 01; 104(9):1171-8.
Score: 0.011